Showing 1531-1540 of 1635 results for "".
- Ash Attia Becomes News CEO of Bionic Vision Technologieshttps://modernod.com/news/ash-attia-becomes-news-ceo-of-bionic-vision-technologies/2476797/Bionic Vision Technologies (BVT) has announced that Ash Attia has been named Chief Executive Officer (CEO), effective July 22. This appointment rounds comes shortly after the appointment of Brian Gordon as Chie
- Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMDhttps://modernod.com/news/opthea-meets-primary-endpoint-in-phase-2b-study-of-opt-302-in-wet-amd/2476795/Opthea announced positive phase 2b results demonstrating that OPT-302 combination therapy met the primary endpoint of superiority in mean visual acuity gain at 24 weeks compared to Lucentis monotherapy in treatment-naïve patients with wet age-related macular degeneration (AMD). <
- Alkahest Phase 2a Study AKST4290-202 in Refractory Wet AMD Meets Primary and Secondary Endpointshttps://modernod.com/news/alkahest-phase-2a-study-akst4290-202-in-refractory-wet-amd-meets-primary-and-secondary-endpoints/2476778/Alkahest announced that its phase 2a trial of AKST4290, an orally-administered small molecule CCR3 inhibitor, met the primary endpoint of achieving an increase in best corrected visual acuity (BCVA) in patients with refractory wet or neovascular age-related macular degeneration (nAMD). AKST4290 w
- Kodiak Sciences Announces Positive Interim Data from Phase 1b Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-announces-positive-interim-data-from-phase-1b-study-of-ksi-301-a-novel-anti-vegf-antibody-biopolymer-conjugate-for-treatment-of-retinal-diseases/2476775/Kodiak Sciences announced positive interim results from the ongoing phase 1b study of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate in patients with anti-VEGF treatment-naïve wet age-related macular degeneration (AMD), diabetic mac
- Eye Surgery Associates Enters Strategic Partnership With Eyecare Services Partnershttps://modernod.com/news/eye-surgery-associates-enters-strategic-partnership-with-eyecare-services-partners/2476743/Eye Surgery Associates, a comprehensive eye care provider in South Florida, has entered into a strategic partnership with Eyecare Services Partners Management, LLC, a national provider of integrated eye care services, effective July 15. Terms of the transaction were not disclosed. Eye Surg
- Children’s Hospital Los Angeles Has Treated 14 Patients With Retinal Degeneration Using Gene Therapyhttps://modernod.com/news/childrens-hospital-los-angeles-has-treated-14-patients-with-retinal-degeneration-using-gene-therapy/2476727/More than a year after becoming one of the first medical institutions nationally to complete a revolutionary gene replacement surgery to restore vision in patients with retinal degeneration, surgeons at The Vision Center at Children’s Hospital Los Angeles (CHLA) have successfully completed the pr
- Avellino Labs Founder Gene Lee Receives 2019 Ellis Island Medal of Honorhttps://modernod.com/news/avellino-labs-founder-gene-lee-receives-2019-ellis-island-medal-of-honor/2476683/Avellino Labs announced the company’s founder, chairman, and president, Gene Lee, is a recipient of a 2019 Ellis Island Medal of Honor. In addition, Mr. Lee has been appointed to the World Economic Forum’s Precision Medicine Council. One of the nation’s most prestigious awards, the Ellis I
- Alimera’s Iluvien Receives Positive NICE Recommendation for Noninfectious Posterior Uveitishttps://modernod.com/news/alimeras-iluvien-receives-positive-nice-recommendation-for-noninfectious-posterior-uveitis/2476675/Alimera Sciences announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE), in its Final Appraisal Determination for national reimbursement, has recommended funding for Iluvien 190 micrograms intravitreal implant in applicator for the prevention of relapse
- The Vision Council Files Joint Letter in Opposition of China 301 Tariffs, Will Testify on Thursdayhttps://modernod.com/news/the-vision-council-files-joint-letter-in-opposition-of-china-301-tariffs-will-testify-on-thursday/2476669/This weekend, The Vision Council, the American Academy of Ophthalmology, National Association of Opticians and Optometrists, Opticians Association of America, National Association of Vision Care Plans, Prevent Blindness, and OneSight jointly filed a letter to the United States Trade Representativ
- A Single Course of Provention’s PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least 2 Yearshttps://modernod.com/news/a-single-course-of-proventions-prv-031-teplizumab-delays-type-1-diabetes-onset-in-high-risk-individuals-by-at-least-2-years/2476644/Provention Bio announced that results from the National Institutes of Health (NIH)-sponsored “At-Risk” Study were published on-line in The New England Journal of Medicine and presented at the Scientific Sessions of the 79th Annual American Diabetes Association (ADA) meeting.